TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Kirk Brown, PhD
Director, CNS Early Development at Alnylam Pharmaceuticals

Profile

Kirk Brown is the Director of CNS RNAi Platform Research and Early Development at Alnylam Pharmaceuticals. His pre-clinical work in rodents and nonhuman primates combining stable siRNA designs with alternative conjugation strategies has enabled potent, long-lasting silencing across the CNS following a single intrathecal administration. In addition to driving RNAi platform innovations Dr. Brown is leading the first CNS RNAi program.

Kirk Brown, PhD's Network

Agenda Sessions

  • Progress in Extrahepatic Silencing with siRNA Conjugates

    , 15:00
  • Progress in Extrahepatic Silencing with siRNA Conjugates

    , 15:00